Live Webinar on "How to Invest successfully to reach goals without losing sleep" Sign up for Live Webinar
investing succesffuly to reach your goals investing succesffuly to reach your goals
X

Welcure Drugs & Pharmaceuticals Ltd Stock Analysis

Small Cap
Evaluated by 144 users | BSE: 524661 | NSE: |
Trading
Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992. Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified...

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Value Creation
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21
Return on Capital Employed 231.61%-14.4%-3.67%-7.67%-274.47%108.82%-65.56%18.1%-49.1%131.83%
Growth Parameters
Growth Parameters Colour Code Guide
Net Sales (Rs. Cr.) 0000.10.10.10.10.10.10.1
Y-o-Y Gr. Rt.-NA33.3%25%100%-10%-44.4%60%0%62.5%
Adjusted EPS (Rs.) -0.080.01000.060.02-0.010-0.010.04
Y-o-Y Gr. Rt.-NA-100%NANA-66.7%-150%NANANA
Book Value per Share (Rs.) -0.08-0.07-0.07-0.060.010.030.020.020.010.06
Adjusted Net Profit -0.10000.100000.1
Net Op. Cash Flow (Rs. Cr.) -0.2000-0.100000
Debt to Cash Flow from Ops 0000000000
Standalone financials take only the parent company into account while consolidated financials take into account financials of the parent company as well as of all its subsidiaries. In most companies consolidated financials should be used for analysis.
Welcure Drugs & Pharmaceuticals Ltd. should be analysed on a Standalone basis
CAGR
CAGR Colour Code Guide
  9 yrs 5 yrs 3 yrs 1 yr
Net Sales NA5.4%37.5%62.5%
Adjusted EPS NA-7.8%NANA
Book Value per Share 043.144.2500
Share Price 5.3% 16.3% 41% 372.2%
Key Financial Parameter
Performance Ratio Colour Code Guide
 Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21
Return on Equity (%) 232.28-14.37-3.62-7.64-274.33108.61-65.817.83-49.46131.66
Operating Profit Margin (%) 0-25.25-27.096.932.4330.86-412.91-11.6441.26
Net Profit Margin (%) 039.487.8111.5885.5930.77-38.84.88-11.3941.34
Debt to Equity 0000000000
Working Capital Days 02553452860109597661
Cash Conversion Cycle 0000000000
Entity Percentage Holding
Promoters 14.12%
Institutions 0.01%
Non-Institutions 85.86%
Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)
Data is not available for this company.

The 5-year analysis of Welcure Drugs & Pharmaceuticals Ltd's performance infers:

Welcure Drugs & Pharmaceuticals Ltd earnings have declined by -7.8%, whereas share price has appreciated 16.3% CAGR over the past five years, indicating the company's share price is likely overvalued. However, for specific investment actions please connect with your investment advisor.

We analysed the performance of Welcure Drugs & Pharmaceuticals Ltd share prices over the last 10 years. Here is what we found out:

Welcure Drugs & Pharmaceuticals Ltd share price has appreciated 3.3% annually over the past ten years.

Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house

Welcure Drugs & Pharmaceuticals Ltd. (WDPL)  was incorporated as a Public Limited Company under the Companies Act, 1956 on 4th June, 1992 and obtained the certificate of commencement of business on 19th June 1992.

Welcure is an Internationally ISO 9001:2000 and WHO-GMP Certified Company. It has to its credit the most modern and sophisticated manufacturing facilities of International Standards which include ultramodern plant, machinery and equipment, own R & D, in house testing laboratory and captive power generation.

Presently, the Company is engaged in the business of manufacture and marketing of pharmaceuticals formulations in the form of tablets, capsules and dry syrups.  The Company is manufacturing over hundred varieties of formulations including antibiotics, sulpha drugs, vitamins, analgesics, antipyretics, corticosteroids, anti-malarials, anti-dysentery, anti-tuberculosis, anti-diabetics, tranquilisers, sedatives and gastro intestinals.  The products of the company have already been well accepted in the domestic markets and the Company has an established customer base.

In March 2000 WDPL entered into a five-year agreement with Bihar Drugs and Chemicals Ltd (BDCL), a subsidiary of Bihar State Pharmaceutical and Chemical Development Corporation Ltd, for manufacturing various pharmaceutical pro ducts (both generic as well as branded) for the latter on loan licence basis. WDPL manufactures the drugs in tablet, capsule and syrup form at its facilities situated in Bhiwadi (Rajasthan).

The Company’s principal activity is to manufacture pharmaceutical products. The products of the Company include tablets, capsules, liquid orals and dry syrups.

Product range of the company includes:

Welcure manufactures a large variety of pharmaceutical formulations, covering almost all ailments, about 250 in numbers. Some of our known products include:

  • Brucure
  • Diclo-plus, Dimcinplus
  • Nimesulide
  • Nimagyltd (tongue dissolvent)
  • Ibucure & Relaxon Forte
  • Coldrest, Alert10004 Coldhistex
  • Cezen & Cezen Forte, Cezen CD
  • Kuffwel
  • X-Dryl, X-Dryl Forte
  • Renact DM
  • Renact DC
  • Diaroban
  • Welcee (Chewable Tab.)
  • Calbiplex
  • Wormicide
  • X-Clox
  • Weloxy-L
  • Welquin
  • Nortin, Cipcin-TNZ
  • Sarvo
  • B-Rest
  • Lopcure
  • Rifampicin, Ethambutol, Rifa-Z
  • Weloxy-P,Amicure-P
  • Norkid
Puchho Befikar
SEBI Registered: Investment Adviser - INA000013323

Callback